Bruschettini Matteo, Romantsik Olga, Zappettini Simona, O'Donnell Colm Pf, Calevo Maria Grazia
Department of Paediatrics, Lund University, Skåne University Hospital, Lund, Sweden.
Cochrane Database Syst Rev. 2019 Feb 1;2(2):CD011724. doi: 10.1002/14651858.CD011724.pub3.
Pneumothorax occurs more frequently in the neonatal period than at any other time of life and is associated with increased mortality and morbidity. It can be treated with either aspiration with a syringe (using a needle or an angiocatheter) or a chest tube inserted in the anterior pleural space and then connected to a Heimlich valve or an underwater seal with continuous suction.
To compare the efficacy and safety of needle aspiration (either with immediate removal of the needle or with the needle left in situ) to intercostal tube drainage in the management of neonatal pneumothorax (PTX).
We used the standard search strategy of Cochrane Neonatal to search the Cochrane Central Register of Controlled Trials (CENTRAL 2018, Issue 5), MEDLINE via PubMed (1966 to 4 June 2018), Embase (1980 to 4 June 2018), and CINAHL (1982 to 4 June 2018). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials.
Randomised controlled trials, quasi-randomised controlled trials and cluster trials comparing needle aspiration (either with the needle or angiocatheter left in situ or removed immediately after aspiration) to intercostal tube drainage in newborn infants with pneumothorax.
For each of the included trials, two authors independently extracted data (e.g. number of participants, birth weight, gestational age, kind of needle and chest tube, choice of intercostal space, pressure and device for drainage) and assessed the risk of bias (e.g. adequacy of randomisation, blinding, completeness of follow-up). The primary outcomes considered in this review are mortality during the neonatal period and during hospitalisation.We used the GRADE approach to assess the quality of evidence.
Two randomised controlled trials (142 infants) met the inclusion criteria of this review. We found no differences in the rates of mortality when the needle was removed immediately after aspiration (risk ratio (RR) 3.92, 95% confidence interval (CI) 0.88 to 17.58; participants = 70; studies = 1) or left in situ (RR 1.50, 95% CI 0.27 to 8.45; participants = 72; studies = 1) or complications related to the procedure. With immediate removal of the needle following aspiration, 30% of the newborns did not require the placement of an intercostal tube drainage. None of the 36 newborns treated with needle aspiration with the angiocatheter left in situ required the placement of an intercostal tube drainage. Overall, the quality of the evidence supporting this finding is very low.
AUTHORS' CONCLUSIONS: There is insufficient evidence to establish the efficacy and safety of needle aspiration and intercostal tube drainage in the management of neonatal pneumothorax. The two included trials showed no differences in mortality; however the information size is low. Needle aspiration reduces the need for intercostal tube drainage placement. Limited or no evidence is available on other clinically relevant outcomes.
气胸在新生儿期比生命中的任何其他时期更频繁发生,并且与死亡率和发病率的增加相关。它可以通过用注射器抽吸(使用针头或血管导管)或在前胸膜腔插入胸管,然后连接到海姆利希瓣膜或持续吸引的水封来治疗。
比较针吸(针头立即拔除或留置原位)与肋间置管引流治疗新生儿气胸(PTX)的疗效和安全性。
我们使用Cochrane新生儿的标准检索策略,检索Cochrane对照试验中心注册库(CENTRAL 2018年第5期)、通过PubMed检索MEDLINE(1966年至2018年6月4日)、Embase(1980年至2018年6月4日)和CINAHL(1982年至2018年6月4日)。我们还检索了临床试验数据库、会议论文集以及检索到的文章的参考文献列表,以查找随机对照试验和半随机试验。
比较针吸(针头或血管导管留置原位或抽吸后立即拔除)与肋间置管引流治疗新生儿气胸的随机对照试验、半随机对照试验和整群试验。
对于每项纳入试验,两位作者独立提取数据(例如参与者数量、出生体重、胎龄、针头和胸管类型、肋间间隙选择、引流压力和装置)并评估偏倚风险(例如随机化的充分性、盲法、随访的完整性)。本综述考虑的主要结局是新生儿期和住院期间的死亡率。我们使用GRADE方法评估证据质量。
两项随机对照试验(142名婴儿)符合本综述的纳入标准。我们发现,抽吸后立即拔除针头时的死亡率(风险比(RR)3.92,95%置信区间(CI)0.88至17.58;参与者 = 70;研究 = 1)或留置原位时的死亡率(RR 1.50,95%CI 0.27至8.45;参与者 = 72;研究 = 1)或与操作相关的并发症方面没有差异。抽吸后立即拔除针头时,30%的新生儿不需要放置肋间置管引流。36名血管导管留置原位进行针吸治疗的新生儿中,无一例需要放置肋间置管引流。总体而言,支持这一发现的证据质量非常低。
没有足够的证据来确定针吸和肋间置管引流治疗新生儿气胸的疗效和安全性。两项纳入试验显示死亡率无差异;然而样本量较小。针吸减少了放置肋间置管引流的必要性。关于其他临床相关结局的证据有限或没有。